Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May;28(2):132-134.
doi: 10.1016/j.tracli.2021.02.005. Epub 2021 Mar 3.

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

D Focosi  1 , M Franchini  2
Affiliations
Editorial

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

D Focosi et al. Transfus Clin Biol. 2021 May.

Abstract

Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs.

Keywords: COVID-19 convalescent plasma; Efficacy; IgG subclasses; Neutralizing antibodies; Pathogen inactivation; Pathogen reduction technologies.

PubMed Disclaimer

Comment in

References

    1. Wong H.K. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010;50:1967–1971. - PubMed
    1. Singh Y. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion. 2006;46:1168–1177. - PMC - PubMed
    1. Bihm D.J. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30 °C. Vox Sang. 2010;98:108–115. - PubMed
    1. FDA . 2020. Recommendations for Investigational COVID-19 Convalescent Plasma. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-in....
    1. European Centre for Diseaase Control (ECDC). Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA – second update 10 December 2020.

Publication types

Substances